Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reddy’s and Hospira lose over US Alimta

Executive Summary

Dr Reddy’s Laboratories and Pfizer’s Hospira unit have suffered defeats in their US litigation over a vitamin regimen patent protecting Eli Lilly’s Alimta (pemetrexed disodium) injectable oncology drug. Lilly expects both of the generics companies to appeal against the ruling by the US district court for the Southern District of Indiana that the alternative salt forms of pemetrexed proposed by the generics firms would infringe US patent 7,772,209, which expires on 24 May 2022, including a six-month paediatric extension.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts